Abstract
Radiation-induced leukemia/lymphomas were induced in C57BL mice using four weekly acute 60Co fractionated irradiation exposures (to 188 cGy, or graded doses of low dose rate (LDR) Cf-252 irradiation given in fractionated exposure sessions at four weekly intervals. The acute 60Co radiation produced 84% thymic lymphomas with a median survival time (MST) of 162 days for mice developing tumors. Mice were exposed to Cf-252 n +,γ radiation in graded doses of 50, 62.5, 80, 112, and 188 cGy per week repeated 4X. Mice exposed to Cf-252 radiation developed thymic lymphomas on a much delayed time schedule. Mice irradiated at 50-80 cGy Cf-252 were killed after the 60Co induced thymoma mice had died to detect tumors. At Cf-252 doses of 112 or 188 rads 79 or 70% of mice, respectively, developed thymic lymphomas and had similar survival times which gave an estimated leukemogenesis RBEn of ∼1.0-2.0. These studies show that for Cf-252 n + γ radiation, compared to 60Co for leukemogenic efficiency, had a much longer latent period, and had a low RBE (1.0-2.0) at the large doses per fraction used in these studies. Under the experimental fractionated conditions tested, Cf-252 neutrons were leukemogenic, but only slightly more so than fractionated 60Co.
| Original language | English |
|---|---|
| Pages (from-to) | 69-74 |
| Number of pages | 6 |
| Journal | International Journal of Radiation Oncology Biology Physics |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1987 |
Bibliographical note
Funding Information:Reprint requests to: Y. Maruyama, Radiation Medicine, Univ. of KY Med Ctr., Lexington, KY 40536. Acknowledgements-Supported in part by contracts and grants from the U.S. Department of Energy, Aiken SC, the Intema-tional Atomic Energy Association, the American Cancer Society, and BRSG grant #RR03374, Division of Research Facilities and Support, N.I.H., Bethesda, M.D. to Dr. Yosh Mam-yama. Mr. Pattarasumunt was a fellow of the IAEA and was
Funding Information:
sponsored by an IAEA grant awarded to Dr. Joseph A. Sayeg, Dept. of Radiation Medicine and Health Radiation Sciences, Univ. of Kentucky, Lexington, Kentucky. We thank L. J. Beach for assistance with the dosimetry, C. Magura for expert technical assistance, and M. J. Howe for expert clerical assistance. Accepted for publication 13 August 1986.
Funding
Reprint requests to: Y. Maruyama, Radiation Medicine, Univ. of KY Med Ctr., Lexington, KY 40536. Acknowledgements-Supported in part by contracts and grants from the U.S. Department of Energy, Aiken SC, the Intema-tional Atomic Energy Association, the American Cancer Society, and BRSG grant #RR03374, Division of Research Facilities and Support, N.I.H., Bethesda, M.D. to Dr. Yosh Mam-yama. Mr. Pattarasumunt was a fellow of the IAEA and was sponsored by an IAEA grant awarded to Dr. Joseph A. Sayeg, Dept. of Radiation Medicine and Health Radiation Sciences, Univ. of Kentucky, Lexington, Kentucky. We thank L. J. Beach for assistance with the dosimetry, C. Magura for expert technical assistance, and M. J. Howe for expert clerical assistance. Accepted for publication 13 August 1986.
| Funders | Funder number |
|---|---|
| University of South Carolina Aiken | |
| BRSG | 03374 |
| Intema-tional Atomic Energy Association | |
| N.I.H. | |
| Michigan State University-U.S. Department of Energy (MSU-DOE) Plant Research Laboratory | |
| American Cancer Society | |
| International Atomic Energy Agency |
Keywords
- Cf-252
- Leukemogenesis
- Neutrons
- Thymic lymphoma
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
